a 83-01 Search Results


95
MedChemExpress hy 10432
Hy 10432, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 10432/product/MedChemExpress
Average 95 stars, based on 1 article reviews
hy 10432 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

94
TargetMol a 83 01
A 83 01, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a 83 01/product/TargetMol
Average 94 stars, based on 1 article reviews
a 83 01 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

96
Tocris a 8301
A 8301, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a 8301/product/Tocris
Average 96 stars, based on 1 article reviews
a 8301 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

98
Tocris a83 01
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
A83 01, supplied by Tocris, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a83 01/product/Tocris
Average 98 stars, based on 1 article reviews
a83 01 - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier

96
MedChemExpress a83 01
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
A83 01, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a83 01/product/MedChemExpress
Average 96 stars, based on 1 article reviews
a83 01 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Selleck Chemicals s7692
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
S7692, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s7692/product/Selleck Chemicals
Average 96 stars, based on 1 article reviews
s7692 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

93
Biogems International growth factor cocktail medium
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
Growth Factor Cocktail Medium, supplied by Biogems International, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/growth factor cocktail medium/product/Biogems International
Average 93 stars, based on 1 article reviews
growth factor cocktail medium - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology a83 01
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
A83 01, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a83 01/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
a83 01 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

94
Tocris a 83 01
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
A 83 01, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a 83 01/product/Tocris
Average 94 stars, based on 1 article reviews
a 83 01 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc neuregulin 1
Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β <t>inhibitor</t> <t>A83‐01</t> (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).
Neuregulin 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/neuregulin 1/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
neuregulin 1 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β inhibitor A83‐01 (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).

Journal: Advanced Science

Article Title: Single‐Cell Morphomechanics of Prostate Cancer‐Associated Fibroblasts Identifies Distinct Features Associated with Patient Outcome

doi: 10.1002/advs.202522440

Figure Lengend Snippet: Modulating TGF‐β signaling changes the morphological and biomechanical features of CAFs and NPFs. a, b) Representative confocal microscopy images of CAFs (a) and NPFs (b) stained for F‐actin, αSMA and nuclei after 48hrs treatment with 10ng mL −1 TGF‐β1 or the TGF‐β inhibitor A83‐01 (and vehicle controls). c, d) Half‐violin plots showing distributions and medians per patient after quantitative analysis of nuclear area (c), and nuclear circularity (d) for three representative patients. Note that F‐actin alignment is not presented due to varying cell densities upon TGF‐β manipulations. e) Median apparent Young's moduli obtained by AFM indentation tests on adherent CAF/NPFs for three patient pairs in dependence on TGF‐β1 and A83‐01 treatment (compared to vehicle controls). f) Representative contour plots from RT‐DC analysis of suspended CAFs and NPFs, showing vehicle controls and cells treated with TGF‐β1 or A83‐01. g, h) Median apparent Young's moduli (h) and volumes i) obtained by RT‐DC for three patient pairs. (c–e, g, h) Results from a linear mixed model statistical analysis are shown ( * p < 0.05, ** p < 0.01, *** p < 0.001). Different donors ( n = 4–5) are highlighted by symbols/patient numbers. See summary of statistical results in Table (Supporting Information).

Article Snippet: A83‐01 , Tocris Bioscience , 5 μ m , , 48 h.

Techniques: Confocal Microscopy, Staining